Spotlight on Dabigatran Etexilate in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation

被引：0
作者：
Karly P. Garnock-Jones
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
Drugs & Aging | 2011年 / 28卷
关键词：
Atrial Fibrillation; Warfarin; Dabigatran; Major Bleeding; Haemorrhagic Stroke;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The need for safe, effective and easily administered and monitored anti-thrombotic treatments that do not have the issues common to warfarin treatment has led to the development of new anticoagulant drugs. Dabigatran etexilate (Pradaxa®, Pradax™) is a prodrug of the direct thrombin inhibitor dabigatran, a direct, reversible, potent inhibitor of thrombin. Dabigatran does not interact with food, and is associated with very few known drug interactions.
引用
收藏
页码：415 / 419
页数：4
相关论文
共 36 条
[1]  
Stangier J(2008)Clinical pharmacokinetics and pharmaco-dynamics of the oral direct thrombin inhibitor dabigatran etexilate Clin Pharmacokinet 47 285-95
[2]  
Wienen W(2007)In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate Thromb Haemost 98 155-62
[3]  
Stassen J-M(2007)Effects of dabigatran, a direct thrombin inhibitor, as compared to the direct factor Xa inhibitors, rivaroxaban and apix-aban, on tissue factor-induced human platelet aggregation in platelet rich plasma Blood 110 558a-70
[4]  
Priepke H(2010)New oral anticoagulants in development Thromb Haemost 103 62-68
[5]  
van Ryn J(2009)Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics Am J Cardiovasc Drugs 9 59-59
[6]  
Kink-Eiband M(2008)Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects Clin Pharmacokinet 47 47-26
[7]  
Hauel N(2007)Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study) Am J Cardiol 100 1419-63
[8]  
Weitz JI(2005)Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement J Clin Pharmacol 45 555-68
[9]  
Stangier J(2010)Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study Clin Pharmacokinet 49 259-1876
[10]  
Rathgen K(2010)Newly identified events in the RE-LY trial N Engl J Med 363 1875-51
1234